Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical carmustine (BCNU) for patch/plaque mycosis fungoides

H S Zackheim1

  • 1Department of Dermatology, University of California, San Francisco.

Seminars in Dermatology
|September 1, 1994
PubMed
Summary

Topical carmustine (BCNU) solution effectively treats mycosis fungoides. High remission rates were observed in early-stage patients, with minimal serious side effects, making it a viable therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of benadryl for urticaria and related dermatoses; a preliminary report.

Archives of dermatology and syphilology·2010
Same author

Sporotrichosis; report of a case in which treatment with iontophoresis was successful.

Archives of dermatology and syphilology·2010
Same author

A modified staging classification for cutaneous T-cell lymphoma.

Journal of the American Academy of Dermatology·2001
Same author

Relative frequency of various forms of primary cutaneous lymphomas.

Journal of the American Academy of Dermatology·2000
Same author

Evidence is lacking for a synergistic or additive effect of combination extracorporeal photopheresis with interferon alfa for cutaneous T-cell lymphoma.

Journal of the American Academy of Dermatology·2000
Same author

Cutaneous T cell lymphoma: update of treatment.

Dermatology (Basel, Switzerland)·1999

Area of Science:

  • Dermatology
  • Oncology

Background:

  • Mycosis fungoides is a type of T-cell lymphoma affecting the skin.
  • Patch and plaque stages represent early-dermatotropic stages of the disease.

Purpose of the Study:

  • To evaluate the efficacy and safety of topical carmustine (BCNU) in patients with patch/plaque stage mycosis fungoides.

Main Methods:

  • A cohort of 172 patients with patch/plaque mycosis fungoides received topical carmustine (BCNU) treatment.
  • Treatment outcomes and side effects were monitored over a 36-month period.

Main Results:

  • Complete or partial remission was achieved in 92% of stage-T1 and 64% of stage-T2 patients at 36 months.
  • The most common side effect was erythema, with some cases developing benign telangiectasias.
  • No secondary skin cancers or significant bone marrow depression were reported.

Conclusions:

  • Topical carmustine (BCNU) demonstrates significant efficacy in treating early-stage mycosis fungoides.
  • The treatment is generally well-tolerated, with a favorable safety profile.

Related Experiment Videos